Stereotaxis Revenue and Competitors

Location

$80M

Total Funding

Estimated Revenue & Valuation

  • Stereotaxis's estimated annual revenue is currently $35M per year.(i)
  • Stereotaxis's estimated revenue per employee is $184,211
  • Stereotaxis's total funding is $80M.

Employee Data

  • Stereotaxis has 190 Employees.(i)
  • Stereotaxis grew their employee count by 0% last year.

Stereotaxis's People

NameTitleEmail/Phone
1
Excecutive Assistant to CEO, VP, General CounselReveal Email/Phone
2
CEO & Chairman Reveal Email/Phone
3
ControllerReveal Email/Phone
4
VP, North American SalesReveal Email/Phone
5
VP APAC Sales & Global TrainingReveal Email/Phone
6
Director, Clinical TrainingReveal Email/Phone
7
Director Clinical Engineering and New ConceptsReveal Email/Phone
8
Director ITReveal Email/Phone
9
Director, Human ResourcesReveal Email/Phone
10
Director, Talent Acquisition (Global)Reveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$24.6M98-4%N/AN/A
#2
$36.6M1462%N/AN/A
#3
$8.5M343%N/AN/A
#4
$2.8M1110%N/AN/A
#5
$75M142-6%N/AN/A
#6
$17.8M7113%N/AN/A
#7
$35M1900%$80MN/A
#8
$12.6M509%N/AN/A
#9
$28.1M112-20%N/AN/A
#10
$9.8M393%N/AN/A
Add Company

What Is Stereotaxis?

Stereotaxis, Inc. is developing solutions in computer integrated interventional medicine. The Company's core technology is a proprietary interventional workstation and toolkit of related disposables (collectively referred to as the "Stereotaxis System") designed to be capable of remotely directing and digitally controlling catheter based therapeutic and diagnostic devices along complex trajectories within the body, providing potential important solutions to major interventional challenges. Stereotaxis received 510(k) clearance from the FDA for its Telstar General Navigation system and bi-plane flat plate digital imaging platform as well as its EP mapping catheter in May 2002.

keywords:Biotechnology

$80M

Total Funding

190

Number of Employees

$35M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Stereotaxis News

2022-04-13 - Stereotaxis (NYSEAMERICAN:STXS) Stock Rating Lowered ...

Stereotaxis (NYSEAMERICAN:STXS) Stock Rating Lowered by Zacks Investment Research. Posted by admin on Apr 21st, 2022.

2022-04-06 - Stereotaxis (NYSEAMERICAN:STXS) Lifted to “Hold” at Zacks ...

Stereotaxis (NYSEAMERICAN:STXS) Lifted to “Hold” at Zacks Investment Research. Posted by admin on Apr 15th, 2022.

2022-04-06 - Stereotaxis to Report First Quarter Financial Results on May 10, 2022 - Benzinga

a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release...

2021-08-30 - Stereotaxis and MicroPort EP Collaborate to Advance Innovation and Adoption of Robotic Electrophysiology in China

ST. LOUIS and SHANGHAI, China, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai Microport EP Medtech Co., Ltd. (“MicroPort EP”) today announced a broad collaboration to advance technology innovation and commercial adoption of robotics in electrophysiology in China. The ag ...

2010-02-25 - Stereotaxis narrows losses in 2009

Stereotaxis Inc. (NSDQ:STXS) reported strong fourth-quarter and year-end sales, helping the company narrow losses nearly 38 percent in 2009. The St. Louis, Mo.-based cardiology instrument control system maker reported a net loss of $6.7 million on $14 million in sales during the three months en ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A1907%N/A
#2
N/A19031%N/A
#3
$46.9M1907%N/A
#4
$37.6M1903%N/A
#5
$21.1M1929%N/A